Induced Pluripotent Stem Cells Market

The Induced Pluripotent Stem Cells (iPSC) are derived from skin or blood cells that have been reprogrammed back into an embryonic-like pluripotent state that enables the development of an unlimited source of any type of human cell needed for therapeutic purposes. The unique properties of iPS cells provides extensive potential to several biopharmaceutical applications. iPSCs are also used in toxicology testing, high throughput, disease modeling, and target identification. This type of stem cell has the potential to transform drug discovery by offering physiologically relevant cells for tool discovery, compound identification, and target validation.  It is a novel medical procedure used for the treatment of cardiac arrhythmias and liver, prostate, kidney, lung, and other forms of cancer.

The global Induced Pluripotent Stem Cells Market is estimated to be valued at USD 1,245.0 million in 2017 and is projected to reach 1,829.3 million by 2023 at a rate of 8.0%. The iPSC market is broadly segmented into hepatocytes, fibroblasts, keratinocytes, amniotic cells, and other cell types. The global induced pluripotent stem cells market is developing rapidly. The primary reason for inclination toward usage of induced pluripotent stem cells is their ability to make any cell or tissue required by the body to defend or combat diseases such as leukemia, spinal cord injury, heart disease, and diabetes. Another advantage is that iPSCs can be created from the tissue of the same patient that will receive the transplantation, thus avoiding immune rejection. Other factors supporting the growth of the market are the increased research funding, growth in number of genomics projects, and increasing use of genome engineering in personalized medicine. However, adverse public of genetic research is likely to restrain the growth of the market.